Merck & Company Inc (MRK)vsStryker Corporation (SYK)
MRK
Merck & Company Inc
$146.72
-0.14%
HEALTHCARE · Cap: $368.89B
SYK
Stryker Corporation
$335.08
-2.75%
HEALTHCARE · Cap: $111.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 156% more annual revenue ($67.38B vs $26.30B). SYK leads profitability with a 13.8% profit margin vs 3.6%. SYK appears more attractively valued with a PEG of 1.37. SYK earns a higher WallStSmart Score of 57/100 (C).
MRK
Hold44
out of 100
Grade: D
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$146.72
$62.06 premium
Margin of Safety
-23.8%
Fair Value
$235.79
Current Price
$335.08
$99.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 20.3%
Generating 1.1B in free cash flow
Areas to Watch
Trading at 8.6x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.37 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
SYK carries more volatility with a beta of 0.78 — expect wider price swings.
SYK is growing revenue faster at 7.6% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (57/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?